Principal Financial Group Inc. Trims Stake in SOPHiA GENETICS SA (NASDAQ:SOPH)

Principal Financial Group Inc. reduced its stake in SOPHiA GENETICS SA (NASDAQ:SOPH) by 3.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,385,013 shares of the company’s stock after selling 43,331 shares during the period. Principal Financial Group Inc. owned 2.08% of SOPHiA GENETICS worth $4,598,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its holdings in shares of SOPHiA GENETICS by 23.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock worth $68,000 after buying an additional 4,115 shares during the last quarter. Silverberg Bernstein Capital Management LLC boosted its position in SOPHiA GENETICS by 54.4% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 34,675 shares of the company’s stock worth $115,000 after acquiring an additional 12,211 shares during the last quarter. Federated Hermes Inc. boosted its position in SOPHiA GENETICS by 40.5% during the fourth quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock worth $312,000 after acquiring an additional 28,819 shares during the last quarter. Bank Pictet & Cie Europe AG raised its stake in SOPHiA GENETICS by 14.4% during the first quarter. Bank Pictet & Cie Europe AG now owns 255,200 shares of the company’s stock worth $847,000 after purchasing an additional 32,200 shares during the period. Finally, Millennium Management LLC raised its stake in SOPHiA GENETICS by 6.5% during the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock worth $2,180,000 after purchasing an additional 42,689 shares during the period. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Trading Up 3.6%

Shares of SOPH stock opened at $3.75 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.94 and a current ratio of 3.11. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $4.92. The stock has a market capitalization of $250.09 million, a P/E ratio of -3.75 and a beta of 1.00. The company has a 50 day moving average price of $3.10 and a 200 day moving average price of $3.24.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 63.47% and a negative net margin of 98.51%. The firm had revenue of $17.78 million for the quarter, compared to analysts’ expectations of $16.76 million. Equities research analysts predict that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.